Recent JNJ News
- Johnson & Johnson to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference • Business Wire • 07/23/2024 08:00:00 PM
- Lawyers for Ovarian Cancer Victims Urge NO Vote on J&J’s Latest Bankruptcy Plan • Business Wire • 07/22/2024 03:59:00 PM
- Johnson & Johnson seeks U.S. FDA approval of SPRAVATO® (esketamine) as the first and only monotherapy for adults with treatment-resistant depression • PR Newswire (US) • 07/22/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/17/2024 12:14:26 PM
- Tech-Led Decline in U.S. Index Futures Pre-Market, Oil Prices Steady After U.S. Inventory Drop • IH Market News • 07/17/2024 10:30:52 AM
- Spirit Airlines Cuts Revenue Forecast, J.B. Hunt Disappoints Analysts’ Estimates, and More Earnings Updates • IH Market News • 07/17/2024 10:28:50 AM
- Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2024 • Business Wire • 07/17/2024 10:25:00 AM
- Johnson & Johnson reports Q2 2024 results • Business Wire • 07/17/2024 10:20:00 AM
- Johnson & Johnson Strengthens Pipeline to Lead in Atopic Dermatitis With the Completion of the Acquisition of Yellow Jersey Therapeutics, Gaining Ownership of NM26 • Business Wire • 07/11/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/09/2024 09:48:38 PM
- Health Canada Authorizes RYBREVANT® (amivantamab) in Combination with Carboplatin and Pemetrexed as the Only Targeted First-line Treatment Approved for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations • PR Newswire (Canada) • 07/03/2024 12:00:00 PM
- Santé Canada autorise le traitement par RYBREVANT® (amivantamab) en association avec le carboplatine et le pemetrexed comme seul traitement de première intention ciblé approuvé pour les patients atteints d'un cancer du poumon non à petites cellules p • PR Newswire (Canada) • 07/03/2024 12:00:00 PM
- CARVYKTI® (ciltacabtagene autoleucel) achieved statistically significant and clinically meaningful improvement in overall survival in landmark CARTITUDE-4 study • PR Newswire (US) • 07/02/2024 11:30:00 AM
- Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class for broadest population of myasthenia gravis patients • PR Newswire (US) • 06/28/2024 03:30:00 PM
- Lawyers for Johnson & Johnson’s Ovarian Cancer Victims React to SCOTUS Decision in Purdue • Business Wire • 06/27/2024 10:46:00 PM
- Johnson & Johnson Completes Acquisition of Proteologix, Inc. • Business Wire • 06/21/2024 11:30:00 AM
- Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the treatment of moderately to severely active Crohn's disease • PR Newswire (US) • 06/20/2024 08:30:00 PM
- More than 60 Law Firms Oppose J&J Prepack Bankruptcy Scheme • Business Wire • 06/20/2024 05:07:00 PM
- TREMFYA® (guselkumab) studies underscore its potential to be the only IL-23 inhibitor to offer both subcutaneous and intravenous induction • PR Newswire (US) • 06/20/2024 12:00:00 PM
- Trump Media Resells Stocks and Warrants; KB Home Exceeds Q2 Expectations, and More News • IH Market News • 06/20/2024 10:55:11 AM
- Beasley Allen and Levin Papantonio: Leading Law Firms Seek Protection for Future Victims of Johnson & Johnson Talc Products • Business Wire • 06/17/2024 09:55:00 PM
- Subcutaneous amivantamab Biologics License Application submitted to U.S. FDA for patients with EGFR-mutated non-small cell lung cancer • PR Newswire (US) • 06/17/2024 12:00:00 PM
- Late-breaking results show nipocalimab significantly improves Sjögren's disease activity in a Phase 2 study • PR Newswire (US) • 06/15/2024 07:30:00 AM
- TALVEY® (talquetamab-tgvs) demonstrates highly durable, longer-term responses in patients with relapsed or refractory multiple myeloma • PR Newswire (US) • 06/14/2024 12:00:00 PM
- Talc Plaintiffs File Motion for Temporary Restraining Order to Limit Johnson & Johnson’s Use of Bankruptcy Strategy • Business Wire • 06/12/2024 06:26:00 PM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM